NEW YORK (GenomeWeb News) – Molecular cytology firm Veracyte has filed for an initial public offering in the US.

The South San Francisco, Calif.-based firm was founded in 2006 as Calderome, but changed its name to Veracyte in early 2008.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Maria Freire from the Foundation for the NIH calls for "politically popular pledges of support" for the NIH to turn into support for increased funding for the agency.

A Thomson Reuters analysis indicates that the life sciences, rather than the tech sector, are increasingly driving global innovation.

The White House says ethical discussions about genome editing of the human germline are needed.

In Genome Research this week: mitochondrial and nuclear gene fusions in cancer, role of genomic imprinting in tissue-specific gene expression, and more.